Jaguar Health, Inc. (JAGX): Total Assets
$38.32M
As of 2025-12-31
$34.19M
As of 2026-06-30
-6.9%
3-year compound annual growth
-2.2%
5-year compound annual growth
+11.9%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $38.32M | -28.3% | 2026-04-07, Balance as of period end |
| 2024-12-31 | $53.42M | +5.2% | 2026-04-07, Balance as of period end |
| 2023-12-31 | $50.76M | +7.0% | 2025-03-31, Balance as of period end |
| 2022-12-31 | $47.45M | -10.9% | 2024-04-01, Balance as of period end |
| 2021-12-31 | $53.27M | +24.3% | 2023-03-24, Balance as of period end |
| 2020-12-31 | $42.84M | +17.7% | 2022-03-11, Balance as of period end |
| 2019-12-31 | $36.41M | -11.3% | 2021-03-31, Balance as of period end |
| 2018-12-31 | $41.04M | -5.9% | 2020-04-03, Balance as of period end |
| 2017-12-31 | $43.63M | n/m | 2019-04-10, Balance as of period end |
| 2016-12-31 | $3.56M | -71.3% | 2018-04-09, Balance as of period end |
| 2015-12-31 | $12.41M | +180.7% | 2017-02-15, Balance as of period end |
| 2014-12-31 | $4.42M | n/a | 2016-03-29, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Jaguar Health, Inc. (JAGX) | 2025-12-31 | $38.32M | -28.3% |
| Prelude Therapeutics Inc (PRLD) | 2025-12-31 | $141.31M | -19.5% |
| Crescent Biopharma, Inc. (CBIO) | 2025-12-31 | $240.29M | +574.7% |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | $21.44M | -9.2% |
| Evommune, Inc. (EVMN) | 2025-12-31 | $224.95M | +195.8% |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | $277.17M | +70.2% |
| Janux Therapeutics, Inc. (JANX) | 2025-12-31 | $1.00B | -5.6% |
| Zenas BioPharma, Inc. (ZBIO) | 2025-12-31 | $383.64M | +3.7% |
| Precigen, Inc. (PGEN) | 2025-12-31 | $155.50M | +7.0% |
Compare JAGX, PRLD, CBIO, EMMA side by side · Screen every company in Pharmaceutical Preparations ↗